PMLiVE23h
AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn
AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...
PMLiVE22h
What’s next for scientific congress booths: five trends for 2025
In 2025, expect to see a continued emphasis on minimizing the environmental footprint of congress booths without compromising ...
PMLiVE23h
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...
PMLiVE23h
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...